FOXO4-DRI
FDA APPROVAL PENDING
Emerging
Longevity
FOXO4-DRI
46
Amino acids
Molecular weight
Peptide
Type
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent 'zombie' cells that accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive. The 'DRI' modification (D-retro-inverso) uses reversed D-amino acids to increase potency and stability. Preclinical research shows restoration of fur density, fitness, and organ function in aged mice.
Top researched benefits
Overview of FOXO4-DRI
FOXO4-DRI competes with FOXO4 for binding to p53, disrupting their protective interaction in senescent cells. This causes p53 to be excluded from the nucleus and triggers cell-intrinsic apoptosis (programmed cell death). Critically, this mechanism is highly selective: the FOXO4-p53 interaction is a specific vulnerability of senescent cells, while FOXO4 is minimally expressed in healthy tissues, leaving functional cells largely unharmed.
Antiaging
- Selectively induces apoptosis in senescent cells while sparing healthy tissue.
- Restores tissue homeostasis and function in naturally aged animal models.
- Improved fitness, mobility, and physical appearance in aged mice.
Organ Function
- Restored renal function in aged and fast-aging mouse models.
- Improved testicular microenvironment and testosterone secretion in aged mice.
- Removes senescent chondrocytes, potentially benefiting joint health.
Chemoprotection
- Neutralizes doxorubicin-induced chemotoxicity by clearing treatment-induced senescent cells.
Storage
Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use immediately or within short term; avoid freeze-thaw cycles
Frequency
3 doses total, administered every other day (Day 1, 3, 5)
Typical Dose
25-33 mg per injection (based on mouse study 5 mg/kg)
Cycle Duration
6 days (3 doses total = 75-100 mg per treatment cycle)
Chemical Makeup
Key benefits
Selective elimination of senescent cells
Restoration of tissue homeostasis
Improved fitness and physical function in aged models
Restored fur density in aged mice
Improved kidney function
Alleviates chemotherapy-induced senescence
Restores testosterone in aged males
Reduces senescent chondrocytes in cartilage
High selectivity spares healthy cells
Community interest
This peptide is still gaining traction in the community.
Senolytic Peptide | p53-FOXO4 Disruptor
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesFOXO4-DRI Molecular Information
View the scientifc details of FOXO4-DRI.
46
Amino Acids
FOXO4-DRI
Leu
Leu
Position 1
Thr
Thr
Position 2
Leu
Leu
Position 3
Arg
Arg
Position 4
Lys
Lys
Position 5
Glu
Glu
Position 6
Pro
Pro
Position 7
Ala
Ala
Position 8
Ser
Ser
Position 9
Glu
Glu
Position 10
Ile
Ile
Position 11
Ala
Ala
Position 12
Gln
Gln
Position 13
Ser
Ser
Position 14
Ile
Ile
Position 15
Leu
Leu
Position 16
Glu
Glu
Position 17
Ala
Ala
Position 18
Tyr
Tyr
Position 19
Ser
Ser
Position 20
Gln
Gln
Position 21
Asn
Asn
Position 22
Gly
Gly
Position 23
Trp
Trp
Position 24
Ala
Ala
Position 25
Asn
Asn
Position 26
Arg
Arg
Position 27
Arg
Arg
Position 28
Ser
Ser
Position 29
Gly
Gly
Position 30
Gly
Gly
Position 31
Lys
Lys
Position 32
Arg
Arg
Position 33
Pro
Pro
Position 34
Pro
Pro
Position 35
Pro
Pro
Position 36
Arg
Arg
Position 37
Arg
Arg
Position 38
Arg
Arg
Position 39
Gln
Gln
Position 40
Arg
Arg
Position 41
Arg
Arg
Position 42
Lys
Lys
Position 43
Lys
Lys
Position 44
Arg
Arg
Position 45
Gly
Gly
Position 46
Molecular Weight
5358DaChain Length
46Amino AcidsType
PeptideFOXO4-DRI Protocols
Currently in experimental stages. The original 2017 mouse study used 5 mg/kg intraperitoneally, three times on alternate days. For a 60kg human, this translates to approximately 25 mg per dose. Self-experimenters have reported using subcutaneous injection. Storage at -20°C required due to peptide stability concerns.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Standard senolytic protocol | 25 | 3 week range | SubQ or IV |
| Mouse study equivalent | 5 | 3 week range | IP (original study) |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Store peptide at -20°C until use
- Reconstitute according to research protocol
- Use immediately or store at 4°C short-term
- Avoid repeated freeze-thaw cycles
FOXO4-DRI Cycle
The FOXO4-DRI Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 0-0
- Senescent cell apoptosis initiated
- Week 0-0
- Clearance of senescent cells
- Week 0-0
- Tissue regeneration and functional improvements
- Week 0-0
- Sustained benefits with periodic treatment
Dosing tools
FOXO4-DRI Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
FOXO4-DRI
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg FOXO4-DRI vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- FOXO4-DRI
- Dosing
- 25-33 mg per injection (based on mouse study 5 mg/kg)
- Dosing Frequency
- 3 doses total, administered every other day (Day 1, 3, 5)
- Cycle Duration
- 6 days (3 doses total = 75-100 mg per treatment cycle)
- Storage
- Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use immediately or within short term; avoid freeze-thaw cycles
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of FOXO4-DRI interactions with other common peptides and substances.
Cognitive
hum
Longevity
Humanin
COMPATIBLE
Different mechanisms; Humanin protects healthy cells while FOXO4-DRI clears senescent ones.
Side effects
Contraindications
Not yet approved for human use
Pregnancy or breastfeeding
Unknown safety in immunocompromised individuals
Active cancer (theoretical - consult oncologist)
Stop signs
Allergic reactions
Unexpected adverse effects
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
FOXO4-DRIResearch References
FOXO4-DRI is an emerging compound
FOXO4-DRI
FOXO4-DRI is an emerging compound
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis
FOXO4-DRI restored fitness, fur density, and renal function in aged mice using 5 mg/kg IP, 3 doses on alternate days. Well-tolerated under therapeutic conditions.
n.d.
An Example of Senolytic Self-Experimentation with FOXO4-DRI
Self-experimenters have translated the mouse protocol to ~25 mg per injection subcutaneously, 3 doses every other day, for 75-100 mg total per treatment cycle.
n.d.
FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency
FOXO4-DRI improved testicular microenvironment and testosterone secretion by clearing senescent Leydig cells.
n.d.
FOXO4-DRI Removes Senescent Cells from Human Chondrocytes
Removed >50% of senescent chondrocytes without affecting healthy early-passage cells.
n.d.
The Disordered p53 Transactivation Domain is the Target of FOXO4-DRI
Structural analysis revealed FOXO4-DRI binds disordered p53TAD2, forming transiently folded complex.
n.d.